Halo Biosciences

Halo Biosciences is a clinical stage biotech redefining the treatment of inflammatory and fibrotic diseases. Halo is developing a novel class of therapeutics that edit the extracellular matrix (ECM). Halo’s lead compound, H02, targets hyaluronan deregulation, a driver of fibrosis, inflammation and edema. Following initial validation of hyaluronan reduction in a Phase 1 study of 4-MU, Halo is currently seeking a $5-8M seed round of financing to develop H02 (reformulated version of 4-MU) into a Phase 2-ready asset for pulmonary hypertension/interstitial lung disease. Halo will also initiate development of proprietary pipeline assets. Our science is based on decades of research from Stanford University that place the extra-cellular matrix at the center of some of today’s most devastating and poorly managed diseases. Our team is composed of multiple translational and clinical world experts in this setting.
Given our work to-date, we believe Halo is a derisked opportunity to develop a new class of therapeutics, solve critical medical problems, and create a major new biotech company.